Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0286
Source ID: NCT03576716
Associated Drug: D6-25-Hydroxyvitamin D3
Title: Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation
Acronym: CLEAR-PLUS
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT03576716/results
Conditions: Chronic Kidney Disease
Interventions: DRUG: D6-25-hydroxyvitamin D3
Outcome Measures: Primary: Change in Metabolic Clearance of D6-25(OH)D3, Metabolic clearance is calculated as the administered dose of 25(OH)D3 divided by the area under the plasma concentration-time curve (AUC). AUC is calculated using the linear trapezoidal method. Change in clearance of D6-25(OH)D3 will be calculated as D6-25(OH)D3 clearance measured during CLEAR-PLUS minus D6-25(OH)D3 clearance previously measured during participation in the related study protocol (without vitamin D3 supplementation). Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration. The change listed is between two timepoints., Baseline, 6 months | Secondary: Change in AUC of D6-25(OH)D3, AUC is calculated using the linear trapezoidal method. Change in the AUC of D6-25(OH)D3 will be calculated as D6-25(OH)D3 AUC measured during CLEAR-PLUS minus D6-25(OH)D3 AUC previously measured during participation in the related study protocol (without vitamin D3 supplementation). Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration. The change listed is between two timepoints., Baseline, 6 months|Change in Terminal Half-life of D6-25(OH)D3, Terminal half-life is equal to ln2/k, where k is the slope of the terminal regression line estimated using ≥3 plasma concentrations. Change in the terminal half-life of D6-25(OH)D3 will be calculated as D6-25(OH)D3 half-life measured during CLEAR-PLUS minus D6-25(OH)D3 half-life previously measured during participation in the related study protocol (without vitamin D3 supplementation). Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration. The change listed is between two timepoints., Baseline, 6 months|Change in Volume of Distribution of D6-25(OH)D3, Volume of distribution in the central compartment is calculated as dose/C0, where dose is the administered dose of 25(OH)D3 and C0 is the initial (estimated) concentration of drug in plasma. Change in the volume of distribution of D6-25(OH)D3 will be calculated as D6-25(OH)D3 volume of distribution measured during CLEAR-PLUS minus D6-25(OH)D3 volume of distribution previously measured during participation in the related study protocol (without vitamin D3 supplementation). Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration. The change listed is between two timepoints., Baseline, 6 months | Other: Changes in Metabolic Formation Clearance of D6-25(OH)D3 Metabolites., Metabolic formation clearance is calculated as the daughter metabolite plasma AUC divided by the AUC of D6-25(OH)D3 (metabolite/parent AUC ratio). AUC is calculated using the linear trapezoidal method. Changes in the metabolic formation clearance of D6-25(OH)D3 metabolites will be calculated as metabolic formation clearance measured during CLEAR-PLUS minus metabolic formation clearance previously measured during participation in the related study protocol (without vitamin D3 supplementation). Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration. The change listed is between two timepoints., Baseline, 6 months|Change in the Serum Concentration of Calcium, Change in the serum concentration of calcium from baseline to 7 days after 25(OH)D3 administration. The change listed is between two timepoints., Baseline, 7 days|Change in the Serum Concentration of Creatinine, Change in the serum concentration of creatinine from baseline to 7 days after 25(OH)D3 administration. The change listed is between two timepoints., Baseline, 7 days|Change in the Serum Concentration of AST, Change in the serum concentration of AST from baseline to 7 days after 25(OH)D3 administration. The change listed is between two timepoints., Baseline, 7 days|Change in the Serum Concentration of ALT, Change in the serum concentration of ALT from baseline to 7 days after 25(OH)D3 administration. The change listed is between two timepoints., Baseline, 7 days
Sponsor/Collaborators: Sponsor: University of Washington | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE1
Enrollment: 19
Study Type: INTERVENTIONAL
Study Designs: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC
Start Date: 2018-06-01
Completion Date: 2021-01-01
Results First Posted: 2021-09-28
Last Update Posted: 2022-05-17
Locations: University of Washington, Seattle, Washington, 98195, United States
URL: https://clinicaltrials.gov/show/NCT03576716